Vertex Pharmaceuticals Incorporated
Every calculator, already run for VRTX
Open the full toolkit →You have the numbers on VRTX. Get the argument.
A written report on which of these readings actually decide the outcome for Vertex Pharmaceuticals Incorporated, what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
32 analysts covering VRTXAnalyst Price Target Disagreement for Vertex Pharmaceuticals Incorporated
Wall Street's bull case implies +33% from the current price; the bear case implies -31%. A 64% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for VRTX
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients wi…
VRTX — frequently asked
Is VRTX a buy right now?
Wall Street's consensus rating on Vertex Pharmaceuticals Incorporated is Buy across 32 analysts, with a mean price target of $571.39 (+13% vs. the current $504.73). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is VRTX overvalued?
VRTX trades at 29.5x trailing earnings, against a DCF fair value of $403 per share. The current price implies 9% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is VRTX's next earnings date?
Vertex Pharmaceuticals Incorporated is next scheduled to report earnings around Nov 2, 2026. A full VRTX research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Vertex Pharmaceuticals Incorporated?
Analysts covering Vertex Pharmaceuticals Incorporated (VRTX) range from a bear-case target of $350.00 to a bull-case high of $672.00, with a mean consensus target of $571.39 across 28 analysts. The spread of $322.00 (64% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Vertex Pharmaceuticals Incorporated against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Vertex Pharmaceuticals Incorporated
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full VRTX research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Vertex Pharmaceuticals Incorporated, in minutes. 3 free reports included with every account — no credit card required.